EDITORIAL
Published on 10 Jun 2024
Editorial: Novel in-vitro and in-vivo strategies to study pancreatic ductal adenocarcinoma progression and chemoresistance
doi 10.3389/fcell.2024.1435209
- 497 views
- Frontiers in Cell and Developmental Biology
- Cancer Cell Biology
- Research Topics
- Novel in-Vitro and in-Vivo Strategies to Study Pancreatic Ductal Adenocarcinoma Progression and Chemoresistance
Novel in-Vitro and in-Vivo Strategies to Study Pancreatic Ductal Adenocarcinoma Progression and Chemoresistance
4,408
Total downloads
13k
Total views and downloads
Submit your idea
You will be redirected to our submission process.
Articles
CASE REPORT
Published on 13 Feb 2024
Case report: Diverse immune responses in advanced pancreatic ductal adenocarcinoma treated with immune checkpoint inhibitor-based conversion therapies
doi 10.3389/fimmu.2024.1326556
- 801 views
BRIEF RESEARCH REPORT
Published on 05 Feb 2024
Hypoxia at 3D organoid establishment selects essential subclones within heterogenous pancreatic cancer
doi 10.3389/fcell.2024.1327772
- 2,464 views
- 2 citations
ORIGINAL RESEARCH
Published on 15 Sep 2023
Laminin 332 expression levels predict clinical outcomes and chemotherapy response in patients with pancreatic adenocarcinoma
doi 10.3389/fcell.2023.1242706
- 3,254 views
- 6 citations
CASE REPORT
Published on 13 Oct 2022
Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review
doi 10.3389/fimmu.2022.1016647
- 2,682 views
- 9 citations
Published in
Frontiers in Cell and Developmental Biology
- Cancer Cell Biology
Impact
- 13kTopic views
- 8,358Article views
- 4,408Article downloads